FDA transparency comments through Nov. 6
This article was originally published in The Rose Sheet
Executive SummaryFDA will accept comments on its transparency initiative through Nov. 6, after which time the Transparency Task Force will conduct its second public meeting. The agency posts initiative information on its transparency Web site, which will operate while the comment docket is open. The task force consists of Principal Deputy Commissioner Josh Sharfstein, the directors of each of FDA's centers, acting Associate Commissioner for Regulatory Affairs Michael Chappell, acting Chief Counsel Michael Landa and acting Chief Scientist Jesse Goodman. Attorney Afia Asamoah, special assistant to Sharfstein, helps staff the task force, and policy analyst Erik Mettler oversees the blog. Commissioner Margaret Hamburg appointed the task force to identify how to improve communication and better explain agency decisions (1"The Rose Sheet" June 15, 2009)
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.